Ocugen Share Price Today
(NASDAQ: OCGN)

Name: Ocugen Share Price Today (NASDAQ: OCGN) - Ocugen Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Ocugen share price is $0.57 & ₹49.57 as on 6 Mar 2025, 2.30 'hrs' IST

$0.57

▲

-0.02

(-2.8%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Ocugen share price in Dollar and Rupees. Guide to invest in Ocugen stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Ocugen, along with analyst recommendations, forecasts, and comprehensive financials.

Ocugen share price movements

Today's Low: $0.55
Today's High: $0.60
$0.57
3.16%
Downside
Day's Volatility :8.0%
Upside
5.0%
52 Weeks Low: $0.57
52 Weeks High: $2.11
$0.57
0.0%
Downside
52 Weeks Volatility :72.92%
Upside
72.92%

Ocugen (OCGN) Returns

Period	Ocugen Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-32.05%	2.1%	0.0%
6 Months	-50.0%	-4.1%	0.0%
1 Year	-32.18%	2.2%	0.0%
3 Years	-76.4%	11.8%	-11.6%

Ocugen (OCGN) Key Statistics

in dollars & INR

Previous Close	$0.59
Open	$0.5869
Today's High	$0.6
Today's Low	$0.552
Market Capitalization	$176.1M
Today's Volume	$875.2K
52 Week High	$2.105
52 Week Low	$0.552
Revenue TTM	$4.7M
EBITDA	$-50.9M
Earnings Per Share (EPS)	$-0.19
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-103.29%

How to invest in Ocugen Stock (OCGN) from India?

It is very easy for Indian residents to invest directly in Ocugen from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Ocugen stock in both Indian Rupees (INR) and US Dollars (USD). Search for Ocugen or OCGN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Ocugen or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Ocugen shares which would translate to 1.526 fractional shares of Ocugen as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Ocugen, in just a few clicks!

Returns in Ocugen (OCGN) for Indian investors in Rupees

The Ocugen stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Ocugen investment value today

Current value as on today

₹70,480

Returns

₹29,520

(-29.52%)

Returns from Ocugen Stock

₹34,483 (-34.48%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Ocugen (OCGN)

-41%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Ocugen Stock from India on INDmoney has decreased by -41% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Ocugen

BlackRock Inc
6.86%
Vanguard Group Inc
5.71%
Geode Capital Management, LLC
2.26%
State Street Corp
2.02%
GMT Capital Corp
0.84%
Northern Trust Corp
0.83%

Analyst Recommendation on Ocugen

Buy

88%Buy

11%Hold

0%Sell

Based on 9 Wall street analysts offering stock ratings for Ocugen(by analysts ranked 0 to 5 stars)

Based on 9 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Ocugen Stock (OCGN)

What analysts predicted

Upside of 1040.35%

Target:

$6.50

Current:

$0.57

Insights on Ocugen Stock (Ticker Symbol: OCGN)

Price Movement
In the last 6 months, OCGN stock has moved down by -50.0%
OCGN vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 93.9%
OCGN vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.7% return, outperforming this stock by 124.4%
Price to Sales
ForOCGN every $1 of sales, investors are willing to pay $32.8, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.8 for every $1 of sales.

Ocugen Technicals Summary

Sell

Neutral

Buy

Ocugen is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Ocugen (OCGN) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Ocugen Inc	-20.51%	-50.0%	-32.18%	-76.4%	49.48%
Regeneron Pharmaceuticals, Inc.	1.3%	-41.29%	-30.51%	9.2%	42.38%
Beone Medicines Ltd	15.19%	34.31%	61.3%	43.16%	68.1%
Vertex Pharmaceuticals Incorporated	3.37%	3.77%	18.06%	106.43%	121.36%
Alnylam Pharmaceuticals, Inc.	-11.52%	-3.4%	62.32%	49.04%	120.93%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Ocugen Inc	NA	NA	NA	-0.2	-1.03	-0.48	NA	0.14
Regeneron Pharmaceuticals, Inc.	17.85	17.85	1.03	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.33	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Ocugen Inc	Buy	$176.1M	49.48%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$74.9B	42.38%	17.85	31.07%
Beone Medicines Ltd	NA	$28.5B	68.1%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.1B	121.36%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.5B	120.93%	NA	-12.37%

About Ocugen

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Organization	Ocugen
Employees	65
CEO	Dr. Shankar Musunuri M.B.A., Ph.D.
Industry	Health Technology

Management People of Ocugen

Name	Title
Dr. Shankar Musunuri M.B.A., Ph.D.	Co-Founder, CEO & Chairman
Dr. Uday B. Kompella Ph.D.	Co-founder & Independent Director
Dr. Arun Upadhyay Ph.D.	Chief Scientific Officer and Head of Research & Development
Mr. Ramesh Ramachandran C.M.A., CPA, M.B.A.	Principal Financial Officer & Principal Accounting Officer
John Kouch J.D.	General Counsel
Ms. Tiffany J. Hamilton M.B.A.	AVP & Head of Corporate Communications
Ms. Kristen Craft	Head of People & Culture
Mr. Michael Shine M.B.A.	Senior Vice President of Commercial
Ms. Jyothy Pillai M.S.	VP & Head of Regulatory & Quality
Dr. Huma Qamar CMI, M.D., M.P.H.	Chief Medical Officer

Important FAQs about investing in OCGN Stock from India :

What is Ocugen share price today?

Ocugen share price today stands at $0.57, Open: $0.59 ; Previous Close: $0.59 ; High: $0.60 ; Low: $0.55 ; 52 Week High: $2.11 ; 52 Week Low: $0.57.

The stock opens at $0.59, after a previous close of $0.59. The stock reached a daily high of $0.60 and a low of $0.55, with a 52-week high of $2.11 and a 52-week low of $0.57.

Can Indians buy Ocugen shares?

Yes, Indians can invest in the Ocugen (OCGN) from India.

With INDmoney, you can buy Ocugen at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Ocugen at zero transaction cost.

How can I buy Ocugen shares from India?

It is very easy to buy Ocugen from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Ocugen (OCGN) be purchased?

Yes, you can buy fractional shares of Ocugen with INDmoney app.

What are the documents required to start investing in Ocugen stocks?

To start investing in Ocugen, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.